» Articles » PMID: 19581922

Obese Men Have Higher-grade and Larger Tumors: an Analysis of the Duke Prostate Center Database

Overview
Specialties Oncology
Urology
Date 2009 Jul 8
PMID 19581922
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is associated with increased risk of positive surgical margins and prostate specific antigen (PSA) recurrence among men undergoing radical prostatectomy. To what degree positive margins contribute to poorer outcome is unclear. Thus, we sought to examine the association between body mass index (BMI) and more objective measures of tumor aggressiveness, tumor grade and size. We carried out a retrospective analysis of 2302 patients treated with radical prostatectomy at the Duke Prostate Center from 1988-2007. Tumor volume was calculated by multiplying prostate weight by percent of specimen involved with cancer. Associations between BMI and tumor volume and high-grade disease (Gleason >or=4+3) independent of pre-operative clinical characteristics of age, race, PSA, clinical stage, biopsy Gleason sum, and year of surgery were assessed using linear and logistic regression, respectively. Mean and median BMI among all subjects was 28.1 and 27.6 kg m(-2), respectively. Increased BMI was significantly associated with younger age (P<0.001), black race (P<0.001), more recent year of surgery (P<0.001), and positive surgical margins (P<0.001). After adjusting for multiple clinical pre-operative characteristics, higher BMI was associated with a greater percent of the prostate involved with cancer (P=0.003), increased tumor volume (P<0.001), and high-grade disease (P=0.007). Men with a BMI >or=35 kg m(2) had nearly 40% larger mean tumor volumes than normal weight men (5.1 versus 3.7 cc), after adjustment for multiple clinical characteristics. In this study, obese men undergoing radical prostatectomy had higher-grade and larger tumors, providing further evidence that obese men undergoing radical prostatectomy have more aggressive prostate cancers.

Citing Articles

Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio.

Dahan J, Pinthus J, Delouya G, Taussky D, Duceppe E, de Jesus A BMC Urol. 2024; 24(1):226.

PMID: 39407194 PMC: 11481316. DOI: 10.1186/s12894-024-01617-2.


Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma.

Liang L, Shang J, Zhang Y, Xu Y, Zhouteng Y, Wen J Aging (Albany NY). 2023; 15(19):10168-10192.

PMID: 37788005 PMC: 10599753. DOI: 10.18632/aging.205065.


Impact of modifiable lifestyle risk factors for prostate cancer prevention: a review of the literature.

Ziglioli F, Patera A, Isgro G, Campobasso D, Guarino G, Maestroni U Front Oncol. 2023; 13:1203791.

PMID: 37746271 PMC: 10515617. DOI: 10.3389/fonc.2023.1203791.


Association between obesity and frequency of high-grade prostate cancer on biopsy in men: A single-center retrospective study.

Baio R, Napodano G, Caruana C, Molisso G, Di Mauro U, Intilla O Mol Clin Oncol. 2022; 17(2):127.

PMID: 35832470 PMC: 9264326. DOI: 10.3892/mco.2022.2560.


The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers.

Leitao C, Matos B, Roque F, Herdeiro M, Fardilha M J Clin Med. 2022; 11(10).

PMID: 35629050 PMC: 9148038. DOI: 10.3390/jcm11102925.